Showing 1941-1950 of 2123 results for "".
- Soticlestat Reduces Seizure Frequency in Developmental and Epileptic Encephalopathieshttps://practicalneurology.com/news/soticlestat-reduces-seizure-frequency-in-developmental-and-epileptic-encephalopathies/2469584/Long-term treatment with soticlestat (OV935/TAK935; Ovid Therapeutics, New York, NY) in individuals with developmental and epileptic encephalopathies (DEE) reduced seizure frequency in the ENDYMION open-label extension study (
- SAGE Cognitive Screening Tool Increased Detection of Cognitive Declinehttps://practicalneurology.com/news/sage-cognitive-screening-tool-increased-detection-of-cognitive-decline/2469582/In a study presented at the American Academy of Neurology Virtual Annual Meeting April 17-22, use of a self-administered gerocognitive examination (SAGE) combined with an informant report of significant cognitive decline over a year increased detection of cognitive impairment 15-fold. SAGE is a w
- Vidofludimus Calcium a Selective T- and B-Cell Reduced Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/vidofludimus-calcium-a-selective-t-and-b-cell-reduced-multiple-sclerosis-disease-activity/2469566/In the phase 2 EMPhASIS trial (NCT03846219) vidofludimus calcium (VFC)(IMU-838; Immunic, New York, NY) reduced new combined unique active (CUA) MRI lesions in individuals with multiple sclerosis (MS). CUA is a measure that counts uniqu
- Ublituximab Treatment Lessened Disability for People With Multiple Sclerosishttps://practicalneurology.com/news/ublituximab-treatment-lessened-disability-for-people-with-multiple-sclerosis/2469565/Treatment of people with relapsing multiple sclerosis (MS) with ublituximab (UTX)(TG Therapeutics; New York, NY) slowed progression of MS as measured with biomarkers and disability progression. Compared with teriflunomide (TFM), ublituximab reduced annualized rate of relapse (ARR), gadolinium enh
- Another Phase 3 Trial of PB-TURSO for Amyotrophic Lateral Sclerosis Being Initiated at FDA Requesthttps://practicalneurology.com/news/another-phase-3-trial-of-pb-turso-for-amyotrophic-lateral-sclerosis-being-initiated-at-fda-request/2469554/A phase 3 trial of sodium phenylbutyrate-taurursodiol (PB-TURSO) (AMX0035; Amylyx Pharmaceuticals, Cambridge, MA) for amyotrophic lateral sclerosis (ALS) is expected to start in the 3rd quarter of 2021. In a nearly 3-year overall survival analysis, those treated with PB-TURSO had a 44% decr
- Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trialhttps://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatmenthttps://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (
- Prescription Patterns in Multiple Sclerosis Changinghttps://practicalneurology.com/news/prescription-patterns-in-multiple-sclerosis-changing/2469504/Neurologists are prescribing more oral disease-modifying therapy (DMT) for initial treatment of multiple sclerosis (MS) than ever. Out of 1,018 individuals with multiple sclerosis (MS) in a 3-month period, close to half received an oral DMT as their first treatment. Only 4 years ago, the proporti
- Lenalidomide for Potential Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/lenalidomide-for-potential-treatment-of-alzheimer-disease-1/2469487/New phase 2 studies are being initiated for lenalidomide (Revlimid; Bristol Myers Squibb, New York, NY), which is an analogue of thalidomide. Eligible participants include those with early-stage Alzheimer disease (AD)/ mild cognitive impairment (MCI). The first study will evaluate the long-term u